Home » Stocks » SSKN

STRATA Skin Sciences, Inc. (SSKN)

Stock Price: $1.88 USD -0.09 (-4.72%)
Updated Feb 25, 2021 1:11 PM EST - Market open
Market Cap 66.53M
Revenue (ttm) 25.27M
Net Income (ttm) -4.49M
Shares Out 33.75M
EPS (ttm) -0.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 25
Last Price $1.88
Previous Close $1.97
Change ($) -0.09
Change (%) -4.72%
Day's Open 1.98
Day's Range 1.87 - 1.99
Day's Volume 59,802
52-Week Range 0.75 - 2.74

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

Preliminary, unaudited fourth quarter revenues in the range of $6.6 million to $6.8 million  Preliminary, unaudited fourth quarter recurring revenues in the range of $5.0 million to $5.2 milli...

GlobeNewsWire - 1 month ago

HORSHAM, Pa., Jan. 06, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated...

GlobeNewsWire - 1 month ago

HORSHAM, Pa., Dec. 28, 2020 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated...

Seeking Alpha - 3 months ago

STRATA Skin Sciences, Inc. (SSKN) CEO Dolev Rafaeli on Q3 2020 Results - Earnings Call Transcript

Benzinga - 3 months ago

Shares of Strata Skin Sciences (NASDAQ:SSKN) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share fell 33.33% year over year to ($0.04), which were i...

GlobeNewsWire - 3 months ago

HORSHAM, Pa., Nov. 10, 2020 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, c...

GlobeNewsWire - 3 months ago

HORSHAM, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, c...

GlobeNewsWire - 3 months ago

HORSHAM, Pa., Nov. 03, 2020 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated...

GlobeNewsWire - 3 months ago

Delivers fastest results with fewest adverse events compared to topical, traditional UV, biologic and systemic therapies  Providing a better solution for I ntegrated H ealth S ystems and Capit...

GlobeNewsWire - 4 months ago

Cigna Now Provides Insurance Coverage of Excimer Laser Therapy for the treatment of Vitiligo Cigna Now Provides Insurance Coverage of Excimer Laser Therapy for the treatment of Vitiligo

GlobeNewsWire - 5 months ago

Company expanding global presence and introducing recurring business model in Japan Company expanding global presence and introducing recurring business model in Japan

GlobeNewsWire - 5 months ago

HORSHAM, Penn., Sept. 08, 2020 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA”), a medical technology company in Dermatology and Plastic Surgery dedicated to developi...

Seeking Alpha - 6 months ago

STRATA Skin Sciences' (SSKN) CEO Dolev Rafaeli on Q2 2020 Results - Earnings Call Transcript

Benzinga - 6 months ago

Shares of Strata Skin Sciences (NASDAQ:SSKN) rose 7.7% in pre-market trading after the company reported Q2 results.

GlobeNewsWire - 6 months ago

Recurring revenue for the second quarter of 2020 was $2.8 million, a 52.1% decrease over second quarter 2019 Total gross margins in the second quarter of 2020 was 48.7%, a 14.9% decrease over...

GlobeNewsWire - 6 months ago

HORSHAM, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicat...

Seeking Alpha - 9 months ago

STRATA Skin Sciences's (SSKN) CEO Dr. Dolev Rafaeli on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

Recurring revenue for the first quarter of 2020 grew 7.3% over first quarter 2019 Total gross margins in the first quarter of 2020 grew 3.8% over first quarter 2019  Global recurring revenue...

GlobeNewsWire - 9 months ago

$2.0 million forgivable loan received Provides further business update - Initiating the Patient Outreach Program

GlobeNewsWire - 10 months ago

Preliminary unaudited total revenue for the first quarter of 2020 is expected to be in the range of $6.7 and $6.9 million, consistent with guidance previously given Global recurring revenue i...

GlobeNewsWire - 10 months ago

92% of participants achieved reduction in mPASI score of 75% or more after receiving Optimal Therapeutic Dose Therapy with the Multi-Micro Dose® diagnostic tip for the treatment of their plaqu...

Seeking Alpha - 11 months ago

STRATA Skin Sciences, Inc. (SSKN) Dolev Rafaeli on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

New features include increased power range, short-hair scalp tip and on-board database to improve patient safety, treatment efficiency and ease-of-use New features include increased power rang...

GlobeNewsWire - 1 year ago

Preliminary, unaudited fourth quarter revenues in the range of $8.8 million to $8.85 million

GlobeNewsWire - 1 year ago

HORSHAM, Pa., Jan. 06, 2020 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicat...

GlobeNewsWire - 1 year ago

HORSHAM, Pa., Nov. 19, 2019 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicat...

GlobeNewsWire - 1 year ago

HORSHAM, Pa., Nov. 14, 2019 (GLOBE NEWSWIRE) -- STRATA Skin Sciences (NASDAQ: SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commer...

Seeking Alpha - 1 year ago

STRATA Skin Sciences, Inc.'s (SSKN) CEO Dolev Rafaeli Hosts Business Update Call (Transcript)

GlobeNewsWire - 1 year ago

Company filed its Annual Report on Form 10-K for the year ended December 31, 2018

GlobeNewsWire - 1 year ago

HORSHAM, Pa., Oct. 07, 2019 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (Nasdaq: SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicat...

GlobeNewsWire - 1 year ago

HORSHAM, Pa., Sept. 10, 2019 (GLOBE NEWSWIRE) -- STRATA Skin Sciences (NASDAQ: SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, comme...

GlobeNewsWire - 1 year ago

HORSHAM, Pa., Aug. 28, 2019 (GLOBE NEWSWIRE) -- STRATA Skin Sciences (NASDAQ: SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commer...

Zacks Investment Research - 1 year ago

Strata Skin (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About SSKN

STRATA Skin Sciences, a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States and Asia. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC excimer laser and VTRAC lamp systems that are used for the treatment of skin disorders, such as psoriasis, vitiligo, atopic dermatitis, and eczema, among others. The company distributes its products internationally through distributors, an... [Read more...]

Industry
Medical Devices
IPO Date
Oct 28, 2005
CEO
Dolev Rafaeli
Employees
115
Stock Exchange
NASDAQ
Ticker Symbol
SSKN
Full Company Profile

Financial Performance

In 2019, SSKN's revenue was $31.59 million, an increase of 5.80% compared to the previous year's $29.86 million. Losses were -$3.60 million, 23.7% more than in 2018.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for SSKN stock is "Strong Buy." The 12-month stock price forecast is 3.92, which is an increase of 108.84% from the latest price.

Price Target
$3.92
(108.84% upside)
Analyst Consensus: Strong Buy